Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
about
Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityGenetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomicsKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa.The genetics of drug efficacy: opportunities and challenges.The global spectrum of protein-coding pharmacogenomic diversity.Predictors of adverse drug reaction-related hospitalisation in Southwest Ethiopia: A prospective cross-sectional study.Adverse effects of carbamazepine monotherapy among patients in Nigeria: a pilot study and implications.Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations.Pharmacogenomic diversity in Singaporean populations and Europeans.The need for an integrated approach for chronic disease research and care in Africa.Global Inequities in Precision Medicine and Molecular Cancer Research
P2860
Q28083100-56CC64E6-C848-4C04-9E80-0671B1FBFDCFQ28601852-E4001C1B-9F45-45F2-A61C-8592C628CC14Q34536677-80A17AF9-FB48-4ACF-80EB-243D38F28E2DQ35183601-49C71589-D7DD-47E8-8818-63C68AD838ABQ36993353-7E8ABBA7-3A53-4579-82D9-7D9B63648F07Q38773033-62A267F5-B6DC-4BE3-996C-B6D4EBEAB4F7Q38806047-116E3267-DA1D-43C2-9D41-EB451BD658C3Q42696007-9B4D96D9-33BD-4A62-B983-7F1A246AD482Q46746109-3FFE9F81-CEB1-426A-AB32-81117B52E62DQ47135784-568C1DED-99FC-40C2-A277-0DE94BDA4875Q48170412-F51B731E-387A-4AE9-90DD-27CD120F7D47Q53541756-53137CFF-FF94-40A1-9CCB-2FE9F1F0FDCAQ55054487-FF1E87EF-3D97-4354-9075-B88469541D4DQ57161225-38574C30-4062-41BC-8470-48DC4E399A72
P2860
Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Higher frequency of genetic va ...... in persons of African descent
@ast
Higher frequency of genetic va ...... in persons of African descent
@en
type
label
Higher frequency of genetic va ...... in persons of African descent
@ast
Higher frequency of genetic va ...... in persons of African descent
@en
prefLabel
Higher frequency of genetic va ...... in persons of African descent
@ast
Higher frequency of genetic va ...... in persons of African descent
@en
P2093
P2860
P356
P1476
Higher frequency of genetic va ...... in persons of African descent
@en
P2093
B C Carleton
C J D Ross
Canadian Pharmacogenomics Network for Drug Safety Consortium
J Sistonen
L R Brunham
M R Hayden
P2860
P2888
P304
P356
10.1038/TPJ.2013.13
P577
2013-04-16T00:00:00Z